The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

Cited by (1,044)

Items 901–1,000 of 1,044

1. Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat
   Lastra, Guido, Whaley-Connell, Adam, Manrique, Camila, Habibi, Javad, Gutweiler, Alex A., Appesh, Lama, Hayden, Melvin R., Wei, Yongzhong, Ferrario, Carlos, Sowers, James R. · 2008 · American Journal of Physiology-Endocrinology and Metabolism
2. Effects of a New Hormone Therapy, Drospirenone and 17-β-Estradiol, in Postmenopausal Women With Hypertension
   White, William B., Hanes, Vladimir, Chauhan, Vijay, Pitt, Bertram · 2006 · Hypertension
3. Evaluation of Continuous Positive Airway Pressure Therapy on Renin–Angiotensin System Activity in Obstructive Sleep Apnea
   Nicholl, David D. M., Hanly, Patrick J., Poulin, Marc J., Handley, George B., Hemmelgarn, Brenda R., Sola, Darlene Y., Ahmed, Sofia B. · 2014 · American Journal of Respiratory and Critical Care Medicine
4. Cardiac Specific Increase in Aldosterone Production Induces Coronary Dysfunction in Aldosterone Synthase–Transgenic Mice
   Anne Garnier, Jennifer K. Bendall, Sébastien Fuchs, Brigitte Escoubet, Francesca Rochais, Jacqueline A. Hoerter, Johnny Nehmé, Marie-Lory Ambroisine, Noeleen De Angelis, Gilles Morineau et al. · 2004 · Circulation
5. Fulminant Myocarditis
   Fredric Ginsberg, Joseph E. Parrillo · 2013 · Critical Care Clinics
6. Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
   Arjun K. Pandey, Deepak L. Bhatt, Avinash K Pandey, Nikolaus Marx, Francesco Cosentino, Ambarish Pandey, Subodh Verma · 2023 · European Heart Journal
7. A reappraisal of loop diuretic choice in heart failure patients
   Jonathan Buggey, Robert John Mentz, Bertram Pitt, Eric L. Eisenstein, Kevin Joseph Anstrom, Eric J. Velazquez, Christopher M. O’Connor · 2015 · American Heart Journal
8. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: A propensity-matched study of the DIG trial
   Ali Ahmed, Bertram Pitt, Shahbudin H. Rahimtoola, Finn Waagstein, Michel White, Thomas E. Love, Eugene Braunwald M. D · 2007 · International Journal of Cardiology
9. ET A Receptor Antagonist Prevents Blood Pressure Elevation and Vascular Remodeling in Aldosterone-Infused Rats
   Jeong Bae Park, Ernesto L. Schiffrin · 2001 · Hypertension
10. Guidelines for the Management of Hypertension for General Practitioners.
    Japanese Society of Hypertension Gu · 2001 · Hypertension Research
11. Smooth Muscle Cell Mineralocorticoid Receptors Are Mandatory for Aldosterone–Salt to Induce Vascular Stiffness
    Guillaume Galmiche, Anne Pizard, Alexandre Gueret, Soumaya El Moghrabi, Antoine Ouvrard‐Pascaud, Stefan Berger, Pascal Challande, Iris Zamir Jaffe, Carlos Labat, Patrick J. Lacolley et al. · 2013 · Hypertension
12. Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction
    Wojciech Kosmala, Aleksandra Rojek, Monika Przewłocka‐Kosmala, Leah M. Wright, Andrzej Mysiak, Thomas Hugh Marwick · 2016 · Journal of the American College of Cardiology
13. Aldosterone Increases Early Atherosclerosis and Promotes Plaque Inflammation Through a Placental Growth Factor‐Dependent Mechanism
    Adam P. McGraw, Jessamyn Bagley, Wei‐Sheng Chen, Carol Galayda, Heather Nickerson, Andrea Armani, Massimiliano Caprio, Peter Carmeliet, Iris Zamir Jaffe · 2013 · Journal of the American Heart Association
14. Uptake of Cardiovascular Drugs Into the Human Heart
    Markus Grube, Henriette E. Meyer zu Schwabedissen, Damaris Präger, Jeanette Haney, Klaus-Uwe Möritz, Konrad Meissner, Dieter Rosskopf, Lothar Eckel, Michael Böhm, Gabriele Jedlitschky et al. · 2006 · Circulation
15. The past, present and future of renin–angiotensin aldosterone system inhibition
    Robert John Mentz, George L. Bakris, Bernard Waeber, John J.V. McMurray, Mihai Gheorghiade, Luis Miguel Ruilope, Aldo Pietro Maggioni, Karl B Swedberg, Ileana L. Piña, Mona Fiuzat et al. · 2012 · International Journal of Cardiology
16. Primary aldosteronism: an update on screening, diagnosis and treatment
    Gian Paolo Rossi, Achille Cesare Pessina, Anthony Michael Heagerty · 2008 · Journal of Hypertension
17. Anti-Remodelling Effect of Canrenone in Patients with Mild Chronic Heart Failure (AREA IN-CHF study): Final Results
    Alessandro Boccanelli, Gian Francesco Mureddu, Giuseppe Cacciatore, Francesco Clemenza, Andrea Di Lenarda, Antonello Gavazzi, Maurizio Porcu, Roberto Latini, Donata Lucci, Aldo Pietro Maggioni et al. · 2009 · European Journal of Heart Failure
18. Alteration of Cardiac and Renal Functions in Transgenic Mice Overexpressing Human Mineralocorticoid Receptor
    Damien Le Menuet, Richard Isnard, Maurice Bichara, Say Viengchareun, Martine Muffat‐Joly, Francine Walker, Maria‐Christina Zennaro, Marc Lombès · 2001 · Journal of Biological Chemistry
19. Improving exercise capacity and quality of life using non‐invasive heart failure treatments: evidence from clinical trials
    Stephan von Haehling, Michael E. Arzt, Wolfram Doehner, Frank Edelmann, Ruben Evertz, Nicole Ebner, Christoph Herrmann‐Lingen, Tania Garfias‐Veitl, Michael Johann Koziolek, Michel Noutsias et al. · 2020 · European Journal of Heart Failure
20. Cardiovascular and Renal Damage in Primary Aldosteronism: Outcomes After Treatment
    Leonardo Alberto Sechi, GianLuca Colussi, Alessandro Di Fabio, Cristiana Catena · 2010 · American Journal of Hypertension
21. Patient selection for left ventricular assist device therapy
    Keith D. Aaronson, Himanshu J. Patel, Francis D. Pagani · 2003 · The Annals of Thoracic Surgery
22. Heart failure clinics and outpatient management: review of the evidence and call for quality assurance
    Finn Gustafsson, J ARNOLD · 2004 · European Heart Journal
23. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
    Agarwal, Rajiv, Anker, Stefan D, Bakris, George, Filippatos, Gerasimos, Pitt, Bertram, Rossing, Peter, Ruilope, Luis, Gebel, Martin, Kolkhof, Peter, Nowack, Christina et al. · 2022 · Nephrology Dialysis Transplantation
24. The Role of the Renin‐Angiotensin‐Aldosterone System in the Pathobiology of Pulmonary Arterial Hypertension (2013 Grover Conference Series)
    Bradley A. Maron, Jane A. Leopold · 2014 · Pulmonary Circulation
25. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt
    William B. Lea, Eun Soo Kwak, James Matthew Luther, Susan M. Fowler, Zuofei Wang, Ji Ma, Agnes B. Fogo, Nancy Jeanne Brown · 2009 · Kidney International
26. Effect of Oral Digoxin in High-Risk Heart Failure Patients: A Pre-Specified Subgroup Analysis of the DIG Trial
    Mihai Gheorghiade, Kanan Patel, Gerasimos S Filippatos, Stefan D. Anker, Dirk Jan van Veldhuisen, John G.F. Cleland, Marco Metra, Inmaculada Aban, Stephen John Greene, Kirkwood F. Adams et al. · 2013 · European Journal of Heart Failure
27. Update on heart failure management and future directions
    Hong‐Mi Choi, Myung‐Soo Park, Jong‐Chan Youn · 2018 · The Korean Journal of Internal Medicine
28. Characteristics, Outcomes, and Treatment of Heart Failure With Improved Ejection Fraction
    Chan Soon Park, Jin Joo Park, Alexandre Mebazaa, Il‐Young Oh, Hyun Ah Park, Hyun‐Jai Cho, Hae‐Young Lee, Kye Hun Kim, Byung‐Su Yoo, Seok‐Min Kang et al. · 2019 · Journal of the American Heart Association
29. Temporal Trends in Clinical Characteristics, Management and Prognosis of Patients With Symptomatic Heart Failure in Japan – Report From the CHART Studies –
    Ryoichi Ushigome, Yasuhiko Sakata, Kotaro Nochioka, Satoshi Miyata, Masanobu Miura, Soichiro Tadaki, Takeshi Yamauchi, Kenjiro Sato, Takeo Onose, Kanako Tsuji et al. · 2015 · Circulation Journal
30. I Diretriz Latino-Americana para avaliação e conduta na insuficiência cardíaca descompensada
    Edimar Alcides Bocchi, Fábio Vilas‐Boas, Sergio V. Perrone, Angel González Caamaño, Nadine Clausell, Maria da Consolação Vieira Moreira, Jorge Mario Thierer, Hugo Grancelli, Carlos Vicente Serrano Junior, Denílson Campos de Albuquerque et al. · 2005 · Arquivos Brasileiros de Cardiologia
31. Current trends in heart failure readmission rates: analysis of medicare data
    Juan M. Aranda, James Wheeler Johnson, JAMIE BETH CONTI · 2009 · Clinical Cardiology
32. Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms
    Murray Epstein, Csaba Pal Kovesdy, Catherine M. Clase, Manish M. Sood, Roberto Pecoits‐Filho · 2022 · American Journal of Kidney Diseases
33. Management of patients receiving implantable cardiac defibrillator shocks: Recommendations for acute and long-term patient management
    Frieder Braunschweig, Giuseppe Boriani, Axel Bauer, Róbert Hatala, Christoph Herrmann‐Lingen, Josef Kautzner, Susanne S. Pedersen, Steen Michael Pehrson, Renato Pietro Ricci, Martin Jan Schalij · 2010 · EP Europace
34. Identification of Benzoxazin-3-one Derivatives as Novel, Potent, and Selective Nonsteroidal Mineralocorticoid Receptor Antagonists
    Tomoaki Hasui, Nobuyuki Matsunaga, Taiichi Ora, Norio Ohyabu, Nobuhiro Nishigaki, Yoshimi Imura, Yumiko Igata, Hideki Matsui, Takashi Motoyaji, Toshimasa Tanaka et al. · 2011 · Journal of Medicinal Chemistry
35. Management of Heart Failure Patient with CKD
    Debasish Banerjee, Giuseppe Rosano, Charles A. Herzog · 2021 · Clinical Journal of the American Society of Nephrology
36. Aldosterone-induced cardiac damage: focus on blood pressure independent effects
    Bernhard M. W. Schmidt · 2003 · American Journal of Hypertension
37. Cost-Effectiveness of Cardiac Resynchronization Therapy in Patients with Symptomatic Heart Failure
    Graham Nichol, Padma Kaul, Ella Huszti, John F. P. Bridges · 2004 · Annals of Internal Medicine
38. Divalent cation transport by the distal nephron: insights from Bartter's and Gitelman's syndromes
    David H. Ellison · 2000 · American Journal of Physiology-Renal Physiology
39. Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la insuficiencia cardíaca crónica. Versión resumida (actualización 2005)
    Grupo de Trabajo de Diagnóstico, Tratamiento de la Insuficiencia Cardíaca Crónica de la Sociedad Europea de Cardiología · 2005 · Revista Española de Cardiología
40. Left Ventricular Assist Devices
    Lynne Warner Stevenson, Eric A. Rose · 2003 · Circulation
41. Effect of Aldosterone and Mineralocorticoid Receptor Blockade on Vascular Inflammation
    Hylton V. Joffe, Gail Kurr Adler · 2005 · Heart Failure Reviews
42. Causes and treatment of oedema in patients with heart failure
    Clark, Andrew L., Cleland, John G. F. · 2013 · Nature Reviews Cardiology
43. Heart failure burden and therapy
    Faiez M. Zannad, Nelly Agrinier, François Alla · 2009 · EP Europace
44. Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction
    Gianluigi Savarese, Hong Xu, Marco Trevisan, Ulf Dahlström, Patrick Rossignol, Bertram Pitt, Lars H. Lund, Juan Jesús Carrero · 2018 · JACC Heart Failure
45. The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure
    Nicola Riccardo Pugliese, Stefano Masi, Stefano Taddei · 2019 · Heart Failure Reviews
46. Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation
    Morag J. Young · 2008 · Current Opinion in Nephrology & Hypertension
47. Drug discovery for heart failure: a new era or the end of the pipeline?
    David M. Kaye, Henry Krum · 2007 · Nature Reviews Drug Discovery
48. Improving the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting: The IMPROVE HF performance improvement registry
    Gregg C. Fonarow, Clyde W. Yancy, Nancy M. Albert, Anne B. Curtis, Wendy Gattis Stough, Mihai Gheorghiade, James Thomas Heywood, Mandeep R. Mehra, Christopher M. O’Connor, DWIGHT W. REYNOLDS et al. · 2007 · American Heart Journal
49. Aldosterone as a Cardiovascular Risk Factor
    Soon Jib Yoo · 2007 · Journal of Korean Endocrine Society
50. Eplerenone: A Selective Aldosterone Receptor Antagonist (SARA)
    John A. Delyani, Ricardo Rocha, Chyung S. Cook, Dwain S. Tolbert, Stuart Levin, Barbara Roniker, Diane L. Workman, Yuen‐lung L. Sing, Brian Whelihan · 2001 · Cardiovascular Drug Reviews
51. Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis
    Neefs, J., van den Berg, N.W.E., Limpens, J., Berger, W.R., Boekholdt, S.M., Sanders, P., de Groot, J.R. · 2017 · International Journal of Cardiology
52. Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis
    Greg H. Tesch, Morag J. Young · 2017 · Frontiers in Pharmacology
53. The Role of the Mineralocorticoid Receptor in Inflammation: Focus on Kidney and Vasculature
    Zachary Belden, Jeffrey A. Deiuliis, Mirela A. Dobre, Sanjay Rajagopalan · 2017 · American Journal of Nephrology
54. Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure
    Gary Michael Felker, Scott David Solomon, Brian Lee Claggett, Rafael Díaz, John J.V. McMurray, Marco Metra, Inder S. Anand, María G. Crespo‐Leiro, Ulf Dahlström, Eva Gonçalvesová et al. · 2021 · JAMA Cardiology
55. Aldosterone Blockade: An Emerging Strategy for Abrogating Progressive Renal Disease
    Murray Epstein · 2006 · The American Journal of Medicine
56. Histone Deacetylase Inhibition Attenuates Transcriptional Activity of Mineralocorticoid Receptor Through Its Acetylation and Prevents Development of Hypertension
    Hae‐Ahm Lee, Dong-Youb Lee, Hyunmin Cho, Sang-Yeob Kim, Yasumasa Iwasaki, In Kyeom Kim · 2013 · Circulation Research
57. 1999 Canadian recommendations for the management of hypertension
    Ross D. Feldman, Norman R.C. Campbell, Pierre M. Larochelle, Peter Bolli, Ellen D. Burgess, S. George Carruthers, John S. Floras, Robert Brian Haynes, George N. Honos, Frans H. H. Leenen et al. · 1999 · Europe PMC (PubMed Central)
58. The Ubiquitous Mineralocorticoid Receptor: Clinical Implications
    Urseline A. Hawkins, Elise P. Gómez-Sánchez, Clara M. Gomez-Sanchez, Celso E. Gómez-Sánchez · 2012 · Current Hypertension Reports
59. Cardioprotective Mechanisms of Eplerenone on Cardiac Performance and Remodeling in Failing Rat Hearts
    Naohiko Kobayashi, Kohtaro Yoshida, Shigefumi Nakano, Tomoyuki Ohno, Takeaki Honda, Yusuke Tsubokou, Hiroaki Matsuoka · 2006 · Hypertension
60. Effects of aldosterone on transient outward K+ current density in rat ventricular myocytes
    Jean‐Pierre Bénitah, Emeline Perrier‐Groult, Ana Maria Gomez, Guy Vassort · 2001 · The Journal of Physiology
61. Blood pressure and amiloride-sensitive sodium channels in vascular and renal cells
    David G. Warnock, Kristina Kusche‐Vihrog, Antoine Tarjus, Shaohu Sheng, Hans Oberleithner, Thomas R. Kleyman, Frédéric Jaisser · 2014 · Nature Reviews Nephrology
62. Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches
    Thomas Unger, Ludovít Paulis, Domenic A. Sica · 2011 · European Heart Journal
63. Coronary Artery Disease
    Peter Andrew McCullough · 2007 · Clinical Journal of the American Society of Nephrology
64. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension
    GianLuca Colussi, Cristiana Catena, Leonardo Antonio Sechi · 2012 · Journal of Hypertension
65. The Cardiorenal Syndrome in Heart Failure
    Kevin Damman, Adriaan A. Voors, Gerjan J Navis, Dirk Jan van Veldhuisen, Hans L. Hillege · 2011 · Progress in Cardiovascular Diseases
66. Aldosterone Stimulates Epidermal Growth Factor Receptor Expression
    Alexander W. Krug, Claudia Großmann, Claudia Schuster, Ruth Freudinger, Sigrid Mildenberger, Manjapra V. Govindan, Michael Gekle · 2003 · Journal of Biological Chemistry
67. Potential of resveratrol in the treatment of heart failure
    Pema Raj, Xavier Lieben Louis, Sijo Joseph Thandapilly, Ali Movahed, Shelley R. Zieroth, Thomas Netticadan · 2013 · Life Sciences
68. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity
    Jazmin M. Pérez‐Rojas, Jorge A. Blanco, Cristino Cruz, Joyce Trujillo, Vishal S. Vaidya, Norma Uribe, Joseph Vincent Bonventre, Gerardo Gamba, Norma Araceli Bobadilla · 2006 · American Journal of Physiology-Renal Physiology
69. Prediction and prevention of sudden cardiac death in heart failure
    Rebecca Lane, Martín Cowie, ANTHONY W.C. CHOW · 2005 · Heart
70. MANAGEMENT OF END STAGE HEART FAILURE
    Erik B. Friedrich, Michael Böhm · 2007 · Heart
71. Myocardial T1 Mapping: Techniques and Potential Applications
    Jeremy R. Burt, Stefan Loy Zimmerman, Ihab R. Kamel, Marc K. Halushka, David A. Bluemke · 2014 · Radiographics
72. Nanomechanics of the Endothelial Glycocalyx
    Zülfü Cem Cosgun, Benedikt Fels, Kristina Kusche‐Vihrog · 2020 · American Journal Of Pathology
73. Synthesis and Evaluation of Heteroaryl-Substituted Dihydronaphthalenes and Indenes: Potent and Selective Inhibitors of Aldosterone Synthase (CYP11B2) for the Treatment of Congestive Heart Failure and Myocardial Fibrosis
    Marieke Voets, Iris Antes, Christiane Scherer, Ursula Müller‐Vieira, Klaus M. Biemel, Sandrine Marchais‐Oberwinkler, Rolf W. Hartmann · 2006 · Journal of Medicinal Chemistry
74. Arterial Pressure, Left Ventricular Mass, and Aldosterone in Essential Hypertension
    Areeg El‐Gharbawy, V NADIG, Jane Morley Kotchen, Clarence E. Grim, Kiran B. Sagar, Mary L. Kaldunski, Pavel Hamet, Zdenka Pausová, Daniel Gaudet, Françis Gossard et al. · 2001 · Hypertension
75. Aldosterone Increases NHE-1 Expression and Induces NHE-1-Dependent Hypertrophy in Neonatal Rat Ventricular Myocytes
    Morris Karmazyn, Que Liu, Xiaohong Tracey Gan, Brenda J. Brix, Larry Fliegel · 2003 · Hypertension
76. Adoption of Spironolactone Therapy for Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction in the United States, 1998–2001
    Frederick A. Masoudi, Cary Philip Gross, Yongfei Wang, Saif S. Rathore, Edward P. Havranek, JoAnne Micale Foody, Harlan M. Krumholz · 2005 · Circulation
77. Heart Failure in African Americans
    Clyde W. Yancy · 2005 · The American Journal of Cardiology
78. 1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension.
    Ross D. Feldman, Norman R.C. Campbell, Pierre M. Larochelle, Peter Bolli, E. D. Burgess, S. George Carruthers, John S. Floras, Robert Brian Haynes, George N. Honos, Frans H. H. Leenen et al. · 1999 · PubMed
79. Efficacy of Spironolactone on Survival in Dogs with Naturally Occurring Mitral Regurgitation Caused by Myxomatous Mitral Valve Disease
    F. Bernay, Martin Bland, Jens U. Häggström, Laure Baduel, Bruno Combes, A. Lopez, Vassilios Kaltsatos · 2010 · Journal of Veterinary Internal Medicine
80. Mineralocorticoid Receptor Antagonists Modulate Galectin-3 and Interleukin-33/ST2 Signaling in Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction
    Antonio Lax, Jesús Sánchez‐Más, M. Lopez, Maria Josefa Fernández‐Del Palacio, Luis Caballero, Iris Paula Garrido, Francisco J. Pastor‐Pérez, James L. Januzzi, Domingo Andrés Pascual-Figal · 2014 · JACC Heart Failure
81. Mineralocorticoid Receptor Antagonism Treats Obesity-Associated Cardiac Diastolic Dysfunction
    Shawn B. Bender, Vincent Gerard DeMarco, Jaume Padilla, Nathan T. Jenkins, Javad Habibi, Mona Garro, Lakshmi Pulakat, Annayya Rao Aroor, Iris Zamir Jaffe, James R. Sowers · 2015 · Hypertension
82. Randomized Pilot Trial Comparing Tolvaptan with Furosemide on Renal and Neurohumoral Effects in Acute Heart Failure
    Kentaro Jujo, Kozue Saito, Issei Ishida, Yuho Furuki, Ahsung Kim, Yuki Suzuki, Haruki Sekiguchi, Junichi Yamaguchi, Hiroshi Ogawa, Nobuhisa Hagiwara · 2016 · ESC Heart Failure
83. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial
    David M. Charytan, Jonathan Himmelfarb, Talat Alp Ikizler, Dominic S. Raj, Jesse Y. Hsu, John Richard Landis, Amanda Hyre Anderson, Adriana M. Hung, Rajnish Mehrotra, Shailendra Sharma et al. · 2018 · Kidney International
84. The cardiac renin–angiotensin system: novel signaling mechanisms related to cardiac growth and function
    David E. Dostal · 2000 · Regulatory Peptides
85. Midterm Benefits of Left Univentricular Pacing in Patients With Congestive Heart Failure
    Jean‐Jacques Blanc, Valérie Valls-Bertault, Marjaneh Fatemi, Martine Gilard, Pierre-Yves Pennec, YVES ETIENNE · 2004 · Circulation
86. Antihypertensive Effects of Drospirenone With 17β-Estradiol, a Novel Hormone Treatment in Postmenopausal Women With Stage 1 Hypertension
    William B. White, Bertram Pitt, Richard Arthur Preston, Vladimir Hanes · 2005 · Circulation
87. 2024 EACTS Guidelines on perioperative medication in adult cardiac surgery
    Anders Jeppsson, (Co-Chairperson) (Sweden), Bianca Rocca, (Co-Chairperson) (Italy), Emma C. Hansson, (Sweden), Tómas Guðbjartsson, (Iceland), Stefan Karl James, (Sweden) et al. · 2024 · European Journal of Cardio-Thoracic Surgery
88. Mineralocorticoid receptors in immune cells: Emerging role in cardiovascular disease
    Nicholas C. Bene, Pilar Alcaide, Henry H. Wortis, Iris Zamir Jaffe · 2014 · Steroids
89. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure
    Mariantonietta Cicoira, Andrea Rossi, Stefano Bonapace, Luisa Zanolla, Giorgio Golia, Lorenzo Franceschini, Beatrice Caruso, Paolo Nicola Marino, Piero Zardini · 2004 · Journal of Cardiac Failure
90. The 45-year story of the development of an anti-aldosterone more specific than spironolactone
    Joël Ménard · 2003 · Molecular and Cellular Endocrinology
91. Management of cardiovascular disease in patients with kidney disease
    Mark R. Kahn, Michael J. Robbins, Michael C. Kim, Valentı́n Fuster · 2013 · Nature Reviews Cardiology
92. A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk Model
    Ramin Shadman, Jeanne E. Poole, Todd Dardas, Dariush Mozaffarian, John G.F. Cleland, Karl B Swedberg, Aldo Pietro Maggioni, Inder S. Anand, Peter E. Carson, Alan Bruce Miller et al. · 2015 · Heart Rhythm
93. Acupuncture inhibits sympathetic activation during mental stress in advanced heart failure patients
    Holly R. Middlekauff, Ka-Kit P. Hui, Jun Liang Yu, Michèle A. Hamilton, Gregg C. Fonarow, Jaime D. Moriguchi, William Robb MacLellan, Antoine Hage · 2002 · Journal of Cardiac Failure
94. Elevated Plasma Aldosterone Levels Despite Complete Inhibition of the Vascular Angiotensin-Converting Enzyme in Chronic Heart Failure
    Ulrich P. Jorde, Timothy J. Vittorio, Stuart D. Katz, P.C. Colombo, Farhana Latif, Thierry H. Le Jemtel · 2002 · Circulation
95. Care Gaps in Adherence to Heart Failure Guidelines
    Jarjour, Marilyne, Henri, Christine, de Denus, Simon, Fortier, Annik, Bouabdallaoui, Nadia, Nigam, Anil, O’Meara, Eileen, Ahnadi, Charaf, White, Michel, Garceau, Patrick et al. · 2020 · JACC: Heart Failure
96. Vascular mineralocorticoid receptor regulates microRNA-155 to promote vasoconstriction and rising blood pressure with aging
    Jennifer J. DuPont, Amy McCurley, Ana Paula Davel, Joseph McCarthy, Shawn B. Bender, Kwangseok Hong, Yan Yang, Jeung‐Ki Yoo, Mark J. Aronovitz, Wendy E. Baur et al. · 2016 · JCI Insight
97. The application of big data to cardiovascular disease: paths to precision medicine
    Jane A. Leopold, Bradley A. Maron, Joseph Loscalzo · 2020 · Journal of Clinical Investigation
98. 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary
    Paul A. Heidenreich, Biykem Bozkurt, David A. Aguilar, Larry A. Allen, Joni J. Byun, Monica M Colvin, Anita M Deswal, Mark H. Drazner, Shannon M. Dunlay, Linda R. Evers et al. · 2022 · Journal of Cardiac Failure
99. Signaling cascades in the failing heart and emerging therapeutic strategies
    Xin He, Tailai Du, Tianxin Long, Xinxue Liao, Yugang Dong, Zhan‐Peng Huang · 2022 · Signal Transduction and Targeted Therapy
100. Edema formation in congestive heart failure and the underlying mechanisms
     Zaid A. Abassi, Emad E. Khoury, Tony Karram, Doron Aronson · 2022 · Frontiers in Cardiovascular Medicine